Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects
Status:
Completed
Trial end date:
2013-09-12
Target enrollment:
Participant gender:
Summary
This study will determine the effect of single and repeat administration of darapladib, a
novel, selective, orally active inhibitor of lipoprotein associated phospholipase A2
(Lp-PLA2) currently under clinical development on the pharmacokinetics of a single oral dose
of midazolam, a cytochrome P450 3A4 (CYP3A4) probe substrate. This study will investigate the
inductive and inhibitory effect of darapladib on CYP3A4 metabolic pathway.